Evidence map›Paper›PMID 40718435›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Combinatorial Effects of Chrysin with Doxorubicin, 5-Fluorouracil, and Cyclophosphamide on Triple-Negative Breast Cancer Cell Line.

Sedighe Yosefi, Hamid Madanchi, Abbas Pakdel, Parviz Kokhaei, Maral Hemati, Negar Sarmadi, Majid Sirati-Sabet

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sedighe Yosefi *Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-5895-7946
Hamid Madanchi *Department of Medical Biotechnology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.ORCID https://orcid.org/0000-0002-6527-7321
Abbas PakdelNervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.ORCID https://orcid.org/0000-0002-7173-367X
Parviz KokhaeiDepartment of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.ORCID https://orcid.org/0000-0001-6544-4209
Maral HematiCancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.ORCID https://orcid.org/0000-0003-3869-598X
Negar SarmadiDepartment of Biochemistry, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.ORCID https://orcid.org/0009-0005-4027-3040
Majid Sirati-SabetDepartment of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-8163-7075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The primary challenges associated with chemotherapy treatment include the development of drug resistance. Chrysin (CH) has the potential to enhance the therapeutic efficacy of conventional chemotherapeutic agents. Additionally, CH, with its antioxidant properties, can reduce the side effects caused by reactive oxygen species (ROS) from chemotherapy. Objectives: This study focused on investigating the combination impact of CH with either 5-fluorouracil (5-FU), doxorubicin (DOX), or cyclophosphamide (CP) on the triple-negative breast cancer (TNBC) MDA-MB-231 cell line. Methods: Cytotoxicity was investigated using the MTT assay. The checkerboard microplate method was utilized to determine the effects of drug interactions. Apoptosis and cell cycle distribution were measured by flow cytometry. The classical scratch assay was used to examine cell migration ability. Results: The combination of 5-FU and DOX showed synergistic effects with CH (FIX < 1). Conversely, the interaction between CH and CP resulted in non-additive effects (FIX > 1). The combination treatment of CH with a chemotherapeutic drug was more effective in inducing early apoptosis than the drug alone and the control (P < 0.05). An increase in the sub-G1 phase was observed upon treatment with the combination of CH and chemotherapeutic drugs compared with the control and drugs alone (P < 0.05). Co-administration of CH with chemotherapeutic drugs induced a significant decrease in cell migration compared with the control and chemotherapeutic drugs alone (P < 0.05). Conclusions: The results revealed that combination therapy involving CH in conjunction with 5-FU and DOX demonstrated a more substantial therapeutic effect on TNBC cells than treatments with 5-FU and DOX individually.

Indexed as

5-FluorouracilChrysin, CyclophosphamideCombinatorial TherapyDoxorubicinTriple-Negative Breast Cancer

Identifiers

PMID40718435
PMCPMC12296718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.